Roche selects Vivonoetics to provide advanced respiratory assessment for the FIREFISH Phase II multicenter clinical trial in infants with Spinal Muscular Atrophy Type 1.

Wednesday, January 25, 2017 Respiratory Disease News
Email Print This Page Comment
Font : A-A+

Roche's FIREFISH clinical trial will evaluate drug efficacy against respiratory muscle function and breathing patterns in infants treated for SMA.

ORANGE COUNTY, Calif., Jan. 24, 2017 /PRNewswire/ -- Vivonoetics Inc., developer of VivoSense® respiratory

testing solutions, announced today that in partnership with Great Lakes NeuroTechnologies, they will be providing advanced respiratory assessment to the Roche FIREFISH study.   

Infants with Spinal muscular atrophy (SMA) develop respiratory insufficiency due to progressive respiratory muscle weakness caused by degeneration of alpha motor neurons in the spinal cord. This weakness results in ineffective airway clearance which is the major cause of morbidity and mortality in infants with SMA.  Thus measurement of longitudinal changes in respiratory muscle function in infants and young children with SMA-1 is critical to the evaluation of interventions targeting SMA-1. Many studies of infants with SMA-1 are significantly hampered by the lack of appropriate respiratory testing tools, suitable for infant use. This results in many SMA-1 trials not appropriately evaluating objective measures of respiratory function.

Accurate measurement of pulmonary ventilation or breathing traditionally requires the use of devices such as masks or mouthpieces coupled to the airway opening. These devices are ill-suited for infant monitoring. As an alternative, the FIREFISH study will be the first large SMA-1 clinical trial to use Respiratory Inductance Plethysmography (RP) systems to non-invasively sense respiratory excursions of the body. By measuring and analyzing the precise patterns of movement of both the chest and abdominal wall, objective measures of pulmonary function may be appropriately evaluated. Specialty analysis of RP data for the evaluation of infant breathing is possible using Vivonoetics' proprietary VivoSense® analysis software together with trained data analysts. Vivonoetics are the leading experts in providing analysis of RP for clinical trials. The VivoSense® analysis is expected to observe clinically significant changes in respiratory morbidity and mortality.  "We strive to advance clinical trials through the use of wearable technology," says Dudley Tabakin, Vivonoetics' Chief Operations Officer. "With our expertise in wearable respiratory sensors and detailed data analytics we have developed a solution that works for monitoring infants with airway obstruction observed in SMA."

RP sensing technology will be provided using the BioRadio from Great Lakes NeuroTechnologies, a wireless, wearable data acquisition system capable of recording RP on infants in real time. RP data are wirelessly transmitted to a computer via Bluetooth and made available to the Vivonoetics analytics team for post-collection processing and analysis. "Great Lakes NeuroTech is very proud to collaborate with Vivonoetics on this exciting study in SMA. This represents successful integration of wearable technology and advanced data analytics to capture infant respiration," says Carissa Simmerman, BioRadio Clinical Trials Manager at Great Lakes NeuroTech. "We are strongly committed to using wearable and remote monitoring technology to make a positive impact on quality of life for those affected by respiratory disorders."

About Vivonoetics, Inc.Vivonoetics Inc. (vivosense.com), Tel: +1 (858) 876-8486, founded in 2009, and based in Newport Beach, CA, is a leader in non-invasive respiratory monitoring technology for clinical research. Through the use of Vivonoetics core laboratory services and VivoSense® technology, pharmaceutical researchers can now obtain high quality data solutions to continually and passively describe a patient's longitudinal pulmonary status in clinical, ambulatory and home settings. Vivonoetics has supported research and clinical trials using VivoSense® at over 500 leading pharmaceutical, research and academic institutions across a wide range of disease states, including sleep disordered breathing, congestive heart failure, chronic obstructive pulmonary disease, Rett Syndrome and cystic fibrosis. For more information, visit www.vivosense.com.

About Great Lakes NeuroTechnologiesGreat Lakes NeuroTechnologies (www.GLNeuroTech.com) is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world.

Contact: Dudley Tabakin, 1-949-933-3429, dudley@vivonoetics.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/roche-selects-vivonoetics-to-provide-advanced-respiratory-assessment-for-the-firefish-phase-ii-multicenter-clinical-trial-in-infants-with-spinal-muscular-atrophy-type-1-300395790.html

SOURCE Vivonoetics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook